(Bloomberg) -- Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste. The deal raised around £2.5 billion ($3.1 billion ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...

Pfizer PFE0.84%increase; green up pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN 0.74%increase; green up pointing triangle for 2.50 billion pounds ...

Jan 15 (Reuters) - Pfizer (PFE.N), opens new tab will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon (HLN.L), opens new tab, lowering its stake in the British consumer healthcare ...

Pfizer plans to cut its stake in Haleon through an accelerated bookbuilding process to institutional investor, starting immediately. The New York drugmaker said Tuesday that the proposed sale ...

Haleon, a global leader in consumer healthcare, has announced its participation in the Dubai International Pharmaceuticals & Technologies Conference & Exhibition (DUPHAT) 2025, the largest ...

Bernstein downgraded Haleon (HLN) to Market Perform from Outperform. Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for ...

Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S. drugmaker said Wednesday ...

Globally, self-care has become synonymous with pampering and luxury. Macelle Erasmus, head of Expert at Haleon SA, calls for a shift in perspective — one that recognises self-care as a critical ...

To calculate this metric for Haleon, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.09 = UK£2.5b ÷ (UK£33b - UK£5.6b ...

Haleon PLC has completed the acquisition of an additional 33% equity interest in its China-based joint venture, Tianjin TSKF Pharmaceutical Co. Ltd, for approximately £0.5 billion. This move ...